Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Changes in Smokers Using Oral Tobacco-derived Nicotine Products.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Voluntary consent to participate in this study documented on the signed informed consent form (ICF).~2. Healthy adult males and females 21 to 65 years of age, inclusive, at Screening~3. Smoking history of an average of at least 10 but no more than 30 factory manufactured combustible cigarettes daily for at least 1 year prior to Screening. Brief periods (i.e., up to 7 consecutive days) of non-smoking during the 3 months prior to Screening (e.g., due to illness or participation in a study where smoking was prohibited) will be permitted.~4. Positive urine cotinine (≥ 500 ng/mL) at Screening.~5. Willing to comply with the requirements of the study.~6. Willing to use all test products after product trial at Check in.~7. Willing and able to abstain from cigarettes from Day 1 through the End of the study.~Exclusion Criteria:~1. Use of any type of tobacco or nicotine containing products other than manufactured cigarettes (e.g., e vapor products, roll-your-own cigarettes, bidis, snuff, nicotine inhaler, pipe, cigar, chewing tobacco, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum) in the 7 days prior to Check in~2. Self-reported puffers (i.e., adult smokers who draw smoke from the cigarette into the mouth and throat but do not inhale).~3. Planning to quit smoking in the next 30 days (from Screening visit).~4. History or presence of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, existing respiratory diseases, immunologic, psychiatric, lymphatic, or cardiovascular disease, or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.~5. Clinically significant abnormal findings on the vital signs, physical examination, medical history, ECG, or clinical laboratory results, in the opinion of the Investigator.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- GROUP 1: Continue Smoking (Type: NO_INTERVENTION): Subjects will be asked to continue smoking their own brand (OB) cigarettes ad libitum for 7 days.
- GROUP 2: OTDN product 1 (Type: EXPERIMENTAL): Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline cigarettes per day (CPD) and use at least 3 oral tobacco-derived nicotine (OTDN) product units per day for 7 days.
- GROUP 3: OTDN product 2 (Type: EXPERIMENTAL): Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 oral tobacco-derived nicotine (OTDN) product units per day for 7 days.
- GROUP 4: OTDN product 1 (Type: EXPERIMENTAL): Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine (OTDN) product, using at least 3 OTDN product units per day for 7 days.
- GROUP 5: OTDN product 2 (Type: EXPERIMENTAL): Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine (OTDN) product, using at least 3 OTDN product units per day for 7 days.
- GROUP 6: Tobacco Cessation (Type: EXPERIMENTAL): Subjects will completely stop all tobacco product usage for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete